Praxis Precision Medicines Inc. Files Prospectus Supplement for New Common Stock Offerings Under 2025 Sales Agreement
Reuters
Sep 06
<a href="https://laohu8.com/S/PRAX">Praxis Precision Medicines</a> Inc. Files Prospectus Supplement for New Common Stock Offerings Under 2025 Sales Agreement
Praxis Precision Medicines Inc. has filed a prospectus supplement with the Commission on September 5, 2025, in connection with the offer and sale of its common stock shares under a new sales agreement. This filing is part of the company's ongoing efforts to manage its capital resources through the 2025 Sales Agreement with Jefferies LLC. Latham & Watkins LLP, serving as the company's legal counsel, has provided an opinion affirming the validity of the shares to be issued and sold. The company recently terminated its 2024 Sales Agreement with Jefferies, having previously sold over 1.3 million shares for gross proceeds of approximately $86.2 million. With the termination, Praxis will not sell additional shares under the previous agreement's program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087865), on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.